title: Cardiovascular consequences of genetic variation at -6/235 in human angiotensinogen using "humanized" gene-targeted mice.
abstract: Genetic and functional data support a role for angiotensinogen in blood pressure control, and many population studies have suggested that polymorphisms in the angiotensinogen gene contribute to hypertension. Two common haplotypes of the human angiotensinogen gene are -6A/235T and -6G/235M. To study their contributions to blood pressure regulation in a controlled model system, we developed triple-transgenic mice expressing either -6A/235T or -6G/235M human angiotensinogen, expressing either an overexpressed and poorly regulated (REN9) or a tightly regulated (PAC160) human renin, and all carrying a null mutation in the endogenous murine angiotensinogen gene. These humanized mice were then examined for blood pressure differences at baseline and after a high-salt diet, changes in cardiovascular organ weight, and differences in angiotensinogen and renin gene expression. Mice expressing the -6G/235M haplotype on the PAC160 background exhibited increased blood pressure and cardiac hypertrophy at baseline. In contrast, all of the mice with the REN9 background had equivalent baseline blood pressures. On the REN9 background, there was a greater increase in blood pressure in -6A/235T in response to a high-salt diet, providing evidence it may be a susceptibility allele. There were no differences in angiotensinogen expression between haplotypes on either background strain. The data suggest that the impact of angiotensinogen haplotypes on cardiovascular end points may be dependent on renin status and environmental influences, such as dietary sodium. These insights may help explain the discrepancies among observational studies that have examined roles for the -6A/235T and -6G/235M angiotensinogen haplotypes in varied human populations.
authors.affiliation: Department of Pharmacology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
authors.forename: Justin L
authors.initials: JL
authors.lastname: Grobe
authors.forename: Matthew E
authors.initials: ME
authors.lastname: Dickson
authors.forename: Sungmi
authors.initials: S
authors.lastname: Park
authors.forename: Deborah R
authors.initials: DR
authors.lastname: Davis
authors.forename: Ella J
authors.initials: EJ
authors.lastname: Born
authors.forename: Curt D
authors.initials: CD
authors.lastname: Sigmund
mesh_terms: D000483:Alleles; D000808:Angiotensinogen / Q000235:genetics* / Q000378:metabolism; D000818:Animals; D001794:Blood Pressure / Q000235:genetics*; D014644:Genetic Variation; D005838:Genotype; D006239:Haplotypes; D006973:Hypertension / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D012083:Renin / Q000235:genetics / Q000378:metabolism; D012982:Sodium, Dietary; D013686:Telemetry
chemical_list: D012982:Sodium, Dietary; D000808:Angiotensinogen; D012083:Renin
references.citation: J Clin Invest. 1997 Sep 15;100(6):1406-15
references.pmid: 9294106
references.citation: Hypertension. 1996 Aug;28(2):290-6
references.pmid: 8707396
references.citation: J Biol Chem. 2000 Jan 14;275(2):1073-8
references.pmid: 10625648
references.citation: J Mol Med (Berl). 1998 Jul;76(8):568-71
references.pmid: 9694433
references.citation: Acta Neurol Scand. 2009 Jun;119(6):356-63
references.pmid: 19473121
references.citation: Circ Res. 1998 Dec 14-28;83(12):1279-88
references.pmid: 9851945
references.citation: Mol Cell Biochem. 1994 Feb 9;131(1):43-7
references.pmid: 8047064
references.citation: Physiol Genomics. 2004 Apr 13;17(2):79-86
references.pmid: 14970360
references.citation: Clin Chim Acta. 2009 Jul;405(1-2):87-93
references.pmid: 19379721
references.citation: Am J Physiol Endocrinol Metab. 2007 May;292(5):E1280-7
references.pmid: 17213477
references.citation: Am J Hum Genet. 1997 Jun;60(6):1448-60
references.pmid: 9199566
references.citation: J Biol Chem. 1999 Dec 10;274(50):35785-93
references.pmid: 10585461
references.citation: Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2735-9
references.pmid: 7708716
references.citation: Circ Res. 1992 May;70(5):1070-9
references.pmid: 1568298
references.citation: J Clin Invest. 1997 Mar 15;99(6):1258-64
references.pmid: 9077534
references.citation: Am J Hypertens. 2004 Jan;17(1):8-13
references.pmid: 14700505
references.citation: J Formos Med Assoc. 2002 Mar;101(3):183-8
references.pmid: 12051013
references.citation: Biomed Environ Sci. 2004 Jun;17(2):209-16
references.pmid: 15386947
references.citation: J Clin Invest. 1997 Apr 1;99(7):1786-97
references.pmid: 9120024
references.citation: Hypertension. 2009 Dec;54(6):1240-7
references.pmid: 19822797
references.citation: J Hypertens. 2008 Jun;26(6):1094-101
references.pmid: 18475146
references.citation: Hypertension. 2006 Jul;48(1):14-20
references.pmid: 16754793
references.citation: J Biol Chem. 1994 Dec 23;269(51):32497-502
references.pmid: 7798251
references.citation: Cell. 1992 Oct 2;71(1):169-80
references.pmid: 1394429
references.citation: Physiol Genomics. 2002 Dec 3;11(3):253-62
references.pmid: 12388794
references.citation: J Am Coll Cardiol. 2001 May;37(6):1536-42
references.pmid: 11345362
references.citation: BMC Cardiovasc Disord. 2005 Apr 05;5(1):7
references.pmid: 15811183
references.citation: Cell Metab. 2008 Mar;7(3):215-26
references.pmid: 18316027